Artificial virus may be key to Chikungunya vaccine
The Asian tiger mosquito is responsible for the transmission of Chikungunya virus, which is most commonly found in tropical and subtropical climates. It is continuously spreading and there is no vaccine to prevent the virus or treatment once it is contracted. The virus has already started epidemics in Southeast Asia, Africa, the Indian Ocean region, Central America, the Caribbean and South America. Experts also estimate that approximately 1.2 million people have been infected with Chikungunya in the U.S.
Recombined segments of the Chikungunya virus’s surface protein called E2 made artificial proteins that may provide protection from the virus when implemented into a small protein fragment vaccine.
"Our research work shows that single and artificially composed fragments of the Chikungunya virus surface protein may suffice to induce a partially protective immune response,” Paul-Ehrlich-Institut professor Barbara Shnierle said. “We consider our vaccine approach as promising for further development."